12:38 AM EDT, 07/13/2026 (MT Newswires) -- OncoZenge (ONCOZ.ST) extended the deadline for the settlement of its 15.1 million-krona subscription agreement with Sichuan Yangtian Bio-Pharmaceutical. The Stockholm-listed clinical-stage pharmaceutical company agreed to further extend the deadline for the investment after receipt of a partial payment of 5 million kronor, according to a July 10 release. The deadline for the remaining payment is now set for Friday, following previous extensions on June 26 and July 3. The subscription agreement was unveiled on June 5.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.